Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
about
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.A data-driven model of biomarker changes in sporadic Alzheimer's disease.Advances in MRI biomarkers for the diagnosis of Alzheimer's disease.Circulating biomarkers that predict incident dementia.Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.(123)I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment.Molecular biomarkers in 2013.Presenilin 2-Dependent Maintenance of Mitochondrial Oxidative Capacity and Morphology.Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer's disease: Correlations and differences between the two methods.Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses.Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT.Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.Aerobic training modulates salience network and default mode network metabolism in subjects with mild cognitive impairment.Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer’s disease
P2860
Q30651551-EC2F67A3-F0DD-4877-8371-E4909CFD8A98Q30835966-F15E7A05-0154-4F8A-8198-53477CF25276Q30870223-10EFECE7-B756-4F31-B6D9-C4ADC976EAC6Q33752058-58EFDFC6-8533-4056-9D0E-A480842DED64Q34450243-88E04D27-8B94-412A-A10A-56408AC4D64EQ35802554-7C245DEA-217F-4298-ABCD-C61190F8F856Q38150708-9702BDD2-7D63-4921-A6E4-DD77CD79D3D9Q41122231-B82EBFEA-9E06-41FB-83BD-BE34D07D328CQ43533587-1F0D1A50-0220-4202-A6CA-10A3BD86851BQ46026707-AA0903C0-A5DC-4645-8649-C7C93F216631Q47104394-E4180A84-5C1C-4C4D-A0E8-71182C7631F5Q47883557-AD15C266-C7F8-467A-9736-BD3AD5C96900Q48449897-702C5BD2-E2DD-40B9-B809-2C5C0B2DD6F7Q48609636-1D375CCB-65DE-4D4C-A2F1-286EBE3F7161Q55439941-D108307A-188C-4545-9755-521F5E74C6B5Q57741276-07B85A64-5ECF-4D13-A528-719EC756FC51
P2860
Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
@en
type
label
Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
@en
prefLabel
Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
@en
P2860
P356
P1476
Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.
@en
P2093
Karl Herholz
P2860
P304
P356
10.2217/BMM.12.51
P577
2012-08-01T00:00:00Z